Literature DB >> 18575761

MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.

Takeshi Kawano1, Rehan Ahmad, Hiroko Nogi, Naoki Agata, Kenneth Anderson, Donald Kufe.   

Abstract

The MUC1 oncoprotein is aberrantly expressed in human multiple myeloma cells by mechanisms that are not understood. Moreover, the functional role of MUC1 in multiple myeloma is not known. The present studies demonstrate that the MUC1 gene locus is amplified in multiple myeloma cell lines and in primary cells from patients. The KMS28PE multiple myeloma cell line, which was found to have MUC1 gene amplification, was stably silenced for MUC1 using different siRNAs. Silencing MUC1 was associated with a decrease in nuclear beta-catenin levels, consistent with the function of MUC1 in stabilizing beta-catenin. MUC1 is also known to activate the IKKbeta-->NF-kappaB pathway and KMS28PE cells silenced for MUC1 were found to have downregulation of IKKbeta and IkappaBalpha phosphorylation, and decreased nuclear targeting of NF-kappaB p65. The results also demonstrate that MUC1: i) contributes to KMS28PE cell proliferation, and ii) protects against apoptosis and loss of self-renewal in the response to melphalan and dexamethasone. These findings indicate that MUC1 activates the beta-catenin and NF-kappaB pathways in multiple myeloma cells and contributes to their growth and survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575761      PMCID: PMC3086751     

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  44 in total

1.  Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion.

Authors:  M Yamamoto; A Bharti; Y Li; D Kufe
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

2.  Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response.

Authors:  Xiaolong Wei; Hai Xu; Donald Kufe
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

3.  SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Authors:  Hiroshi Yasui; Teru Hideshima; Makoto Hamasaki; Aldo M Roccaro; Norihiko Shiraishi; Shaji Kumar; Pierfrancesco Tassone; Kenji Ishitsuka; Noopur Raje; Yu-Tzu Tai; Klaus Podar; Dharminder Chauhan; Lorenzo M Leoni; Sarath Kanekal; Gary Elliott; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

4.  MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.

Authors:  Lei Huang; Dongshu Chen; Derek Liu; Li Yin; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

6.  MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.

Authors:  Xiaolong Wei; Hai Xu; Donald Kufe
Journal:  Mol Cell       Date:  2006-01-20       Impact factor: 17.970

7.  Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

Authors:  Carmen Choi; Mathias Witzens; Marianna Bucur; Markus Feuerer; Nora Sommerfeldt; Andreas Trojan; Anthony Ho; Volker Schirrmacher; Hartmut Goldschmidt; Philipp Beckhove
Journal:  Blood       Date:  2004-11-23       Impact factor: 22.113

8.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

Authors:  D Chauhan; H Uchiyama; Y Akbarali; M Urashima; K Yamamoto; T A Libermann; K C Anderson
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

9.  Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin.

Authors:  Y Li; A Bharti; D Chen; J Gong; D Kufe
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.

Authors:  S P Treon; J A Mollick; M Urashima; G Teoh; D Chauhan; A Ogata; N Raje; J H Hilgers; L Nadler; A R Belch; L M Pilarski; K C Anderson
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

View more
  23 in total

Review 1.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

2.  Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.

Authors:  Mengying Yao; Weihong Zhang; Qingxian Zhang; Lihua Xing; Aiguo Xu; Qiuhong Liu; Bing Cui
Journal:  Lung       Date:  2011-10-01       Impact factor: 2.584

3.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

4.  Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Authors:  Michal Bar-Natan; Dina Stroopinsky; Katarina Luptakova; Maxwell D Coll; Arie Apel; Hasan Rajabi; Athalia R Pyzer; Kristen Palmer; Michaela R Reagan; Myrna R Nahas; Rebecca Karp Leaf; Salvia Jain; Jon Arnason; Irene M Ghobrial; Kenneth C Anderson; Donald Kufe; Jacalyn Rosenblatt; David Avigan
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

5.  Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.

Authors:  Li Yin; Rehan Ahmad; Michio Kosugi; Turner Kufe; Baldev Vasir; David Avigan; Surender Kharbanda; Donald Kufe
Journal:  Mol Pharmacol       Date:  2010-05-05       Impact factor: 4.436

6.  Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.

Authors:  Li Yin; Turner Kufe; David Avigan; Donald Kufe
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

7.  Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.

Authors:  Li Yin; Michio Kosugi; Donald Kufe
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

Review 8.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

Review 9.  MUC1 in hematological malignancies.

Authors:  Dina Stroopinsky; Donald Kufe; David Avigan
Journal:  Leuk Lymphoma       Date:  2016-06-27

10.  MUC1 mucin interacts with calcium-modulating cyclophilin ligand.

Authors:  Wei Guang; K Chul Kim; Erik P Lillehoj
Journal:  Int J Biochem Cell Biol       Date:  2008-12-14       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.